1037.3000 -10.55 (-1.01%)
NSE Sep 19, 2025 15:31 PM
Volume: 1.1M
 

1037.30
-1.01%
Reliance Securities
ff CDH has filed total 6 transdermal products and plans to file one (Lidocaine) in Q4FY17E. Management indicated the product pipeline of recently acquired Sentynl will be launched in next 18 months though revenue contribution would...
Zydus Lifesciences L.. has an average target of 1045.33 from 6 brokers.
More from Zydus Lifesciences Ltd.
Recommended